Search - tctmd.com

Displaying 561 - 580 of 2239

Sort: Relevancy | Date

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

News Daily News

Class I Recall for Cordis’ Super Torque Catheters with Radiopaque Markers

Michael O'Riordan

September 23, 2021

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

September 20, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

Renal Denervation a Third Option for Hypertension, European Experts Say

News Daily News

Renal Denervation a Third Option for Hypertension, European Experts Say

September 17, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

COVID-19: TCTMD’s Daily Dispatch for September Week 3

News Daily News

COVID-19: TCTMD’s Daily Dispatch for September Week 3

September 13, 2021

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

News Daily News

Switching to Tenecteplase for Stroke Thrombolysis May Boost Outcomes

September 09, 2021

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

News Daily News

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

September 07, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

News Conference News ESC 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Michael O'Riordan

August 30, 2021

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

August 30, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Expired Cardiac Devices May Do Global Good, but Safety Unknown

News Features

Expired Cardiac Devices May Do Global Good, but Safety Unknown

Yael L. Maxwell

August 26, 2021

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

News Daily News

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Michael O'Riordan

August 26, 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

August 24, 2021

COVID-19: TCTMD’s Daily Dispatch for August Week 4

News Daily News

COVID-19: TCTMD’s Daily Dispatch for August Week 4

August 22, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.